Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BCAX Bicara Therapeutics	$8.71 -1.1%	$12.06	$7.80 ▼ $28.09	$475.01M	N/A	598,644 shs	2.70 million shs
REPL Replimune Group	$9.33 -1.4%	$9.00	$6.44 ▼ $17.00	$719.22M	0.63	859,630 shs	1.40 million shs
VYGR Voyager Therapeutics	$2.96 -0.3%	$3.24	$2.65 ▼ $9.55	$163.79M	0.82	476,366 shs	1.08 million shs
XNCR Xencor	$8.14 -3.1%	$8.96	$7.16 ▼ $27.24	$579.33M	0.87	675,868 shs	1.62 million shs

13 Stocks Institutional Investors Won't Stop Buying

Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BCAX Bicara Therapeutics	-1.14%	-6.55%	-7.93%	-35.00%	+870,999,900.00%
REPL Replimune Group	-1.37%	+0.65%	+10.68%	-10.20%	+7.12%
VYGR Voyager Therapeutics	-0.34%	-0.34%	+8.42%	-18.90%	-62.05%
XNCR Xencor	-3.10%	-4.68%	+7.81%	-27.52%	-58.11%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BCAX Bicara Therapeutics	2.1533 of 5 stars	3.5	0.0	0.0	1.5	0.8	1.3
REPL Replimune Group	3.9582 of 5 stars	3.6	1.0	4.5	1.4	2.5	0.6
VYGR Voyager Therapeutics	4.0474 of 5 stars	3.6	1.0	4.6	2.7	1.7	0.6
XNCR Xencor	4.0762 of 5 stars	3.4	2.0	3.9	2.7	0.8	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BCAX Bicara Therapeutics	3.00	Buy	$31.86	265.77% Upside
REPL Replimune Group	3.13	Buy	$20.83	123.29% Upside
VYGR Voyager Therapeutics	3.13	Buy	$13.39	352.36% Upside
XNCR Xencor	2.75	Moderate Buy	$28.00	243.98% Upside

Current Analyst Ratings Breakdown

Latest VYGR, REPL, BCAX, and XNCR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/20/2025	REPL Replimune Group	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight
6/2/2025	REPL Replimune Group	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$14.00 ➝ $22.00
5/23/2025	BCAX Bicara Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Underweight ➝ Equal Weight	$8.00
5/23/2025	BCAX Bicara Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$30.00
5/16/2025	BCAX Bicara Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$44.00 ➝ $41.00
5/8/2025	XNCR Xencor	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Underweight ➝ Underweight	$22.00 ➝ $6.00
4/30/2025	XNCR Xencor	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$31.00
4/21/2025	XNCR Xencor	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform
4/17/2025	BCAX Bicara Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Underweight	$8.00
4/8/2025	VYGR Voyager Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00 ➝ $30.00
4/7/2025	BCAX Bicara Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$45.00 ➝ $44.00

(Data available from 6/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BCAX Bicara Therapeutics	N/A	N/A	N/A	N/A	$9.04 per share	N/A
REPL Replimune Group	N/A	N/A	N/A	N/A	$5.40 per share	N/A
VYGR Voyager Therapeutics	$80M	2.05	N/A	N/A	$5.49 per share	0.54
XNCR Xencor	$110.49M	5.24	N/A	N/A	$9.63 per share	0.85

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BCAX Bicara Therapeutics	-$68M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	8/12/2025 (Estimated)
REPL Replimune Group	-$247.30M	-$3.07	N/A	N/A	N/A	N/A	-57.98%	-45.21%	8/6/2025 (Estimated)
VYGR Voyager Therapeutics	-$65M	-$1.46	N/A	N/A	N/A	-126.49%	-27.36%	-21.06%	8/5/2025 (Estimated)
XNCR Xencor	-$232.62M	-$3.06	N/A	N/A	N/A	-181.17%	-31.94%	-22.19%	8/4/2025 (Estimated)

Latest VYGR, REPL, BCAX, and XNCR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/22/2025	Q4 2025	REPL Replimune Group	-$0.75	-$0.82	-$0.07	-$0.82	N/A	N/A
5/13/2025	Q1 2025	BCAX Bicara Therapeutics	-$0.40	-$0.68	-$0.28	-$0.68	N/A	N/A
5/8/2025	Q1 2025	XNCR Xencor	-$0.60	-$0.66	-$0.06	-$0.66	$23.44 million	$32.73 million
5/6/2025	Q1 2025	VYGR Voyager Therapeutics	-$0.35	-$0.53	-$0.18	-$0.53	$13.55 million	$6.47 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BCAX Bicara Therapeutics	N/A	N/A	N/A	N/A	N/A
REPL Replimune Group	N/A	N/A	N/A	N/A	N/A
VYGR Voyager Therapeutics	N/A	N/A	N/A	N/A	N/A
XNCR Xencor	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BCAX Bicara Therapeutics	N/A	24.62	24.62
REPL Replimune Group	0.17	7.95	7.95
VYGR Voyager Therapeutics	N/A	6.10	6.10
XNCR Xencor	0.16	5.89	5.89

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BCAX Bicara Therapeutics	N/A
REPL Replimune Group	92.53%
VYGR Voyager Therapeutics	48.03%
XNCR Xencor	N/A

Insider Ownership

Company	Insider Ownership
BCAX Bicara Therapeutics	15.50%
REPL Replimune Group	8.80%
VYGR Voyager Therapeutics	6.39%
XNCR Xencor	4.76%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BCAX Bicara Therapeutics	32	54.54 million	46.08 million	N/A
REPL Replimune Group	210	77.09 million	70.30 million	Optionable
VYGR Voyager Therapeutics	100	55.34 million	51.80 million	Optionable
XNCR Xencor	280	71.17 million	67.78 million	Optionable

VYGR, REPL, BCAX, and XNCR Headlines

Recent News About These Companies

Xencor (NASDAQ:XNCR) Stock Price Down 5.7% on Insider Selling

June 18, 2025 | americanbankingnews.com

Xencor (NASDAQ:XNCR) Shares Down 5.7% on Insider Selling

June 17, 2025 | marketbeat.com

Insider Selling: Xencor, Inc. (NASDAQ:XNCR) Director Sells 2,215 Shares of Stock

June 17, 2025 | insidertrades.com

Insider Selling: Xencor, Inc. (NASDAQ:XNCR) Director Sells 2,215 Shares of Stock

June 16, 2025 | marketbeat.com

Kurt A. Gustafson Sells 2,993 Shares of Xencor, Inc. (NASDAQ:XNCR) Stock

June 16, 2025 | marketbeat.com

Xencor, Inc. (NASDAQ:XNCR) Director Sells $27,595.46 in Stock

June 16, 2025 | marketbeat.com

Xencor, Inc. (NASDAQ:XNCR) Director Ellen Feigal Sells 2,993 Shares

June 16, 2025 | marketbeat.com

Xencor (NASDAQ:XNCR) Trading Up 6.3% - Here's What Happened

June 10, 2025 | marketbeat.com

Bank of America Corp DE Sells 585,930 Shares of Xencor, Inc. (NASDAQ:XNCR)

June 9, 2025 | marketbeat.com

27,491 Shares in Xencor, Inc. (NASDAQ:XNCR) Acquired by Wellington Management Group LLP

June 8, 2025 | marketbeat.com

Xencor, Inc. (NASDAQ:XNCR) Receives Average Recommendation of "Moderate Buy" from Brokerages

June 8, 2025 | marketbeat.com

Public Employees Retirement System of Ohio Purchases New Holdings in Xencor, Inc. (NASDAQ:XNCR)

June 3, 2025 | marketbeat.com

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Clover Health Investments (CLOV), Xencor (XNCR) and Intellia Therapeutics (NTLA)

May 13, 2025 | theglobeandmail.com

Xencor Reports First Quarter 2025 Financial Results

May 7, 2025 | uk.finance.yahoo.com

Xencor (XNCR) Reports Q1 Loss, Tops Revenue Estimates

May 7, 2025 | zacks.com

Xencor, Inc. (NASDAQ:XNCR) EVP Nancy Valente Sells 4,616 Shares

May 7, 2025 | insidertrades.com

Will Xencor (XNCR) Report Negative Q1 Earnings? What You Should Know

May 1, 2025 | zacks.com

William Blair starts Xencor stock with Outperform rating

April 23, 2025 | uk.investing.com

William Blair Initiates Coverage of Xencor (XNCR) with Outperform Recommendation

April 22, 2025 | msn.com

Xencor initiated with an Outperform at William Blair

April 21, 2025 | markets.businessinsider.com

Xencor participates in a conference call with JPMorgan

April 18, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
By Dan Schmidt | June 20, 2025
View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
3 Defense Stocks That Will Profit From a Golden Dome
By Chris Markoch | May 30, 2025
View 3 Defense Stocks That Will Profit From a Golden Dome
BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
By Gabriel Osorio-Mazilli | June 23, 2025
View BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
Intel's Turnaround Strategy Shifts From Planning to Attack Mode
By Jeffrey Neal Johnson | June 20, 2025
View Intel's Turnaround Strategy Shifts From Planning to Attack Mode
Payment Giants Slide on Stablecoin Buzz—Is Now the Time to Buy?
By Gabriel Osorio-Mazilli | June 23, 2025
View Payment Giants Slide on Stablecoin Buzz—Is Now the Time to Buy?

VYGR, REPL, BCAX, and XNCR Company Descriptions

Bicara Therapeutics NASDAQ:BCAX

$8.71 -0.10 (-1.14%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$8.75 +0.04 (+0.46%)

As of 06/27/2025 07:47 PM Eastern

Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.

Replimune Group NASDAQ:REPL

$9.33 -0.13 (-1.37%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$9.33 0.00 (0.00%)

As of 06/27/2025 07:59 PM Eastern

Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.

Voyager Therapeutics NASDAQ:VYGR

$2.96 -0.01 (-0.34%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$2.94 -0.02 (-0.64%)

As of 06/27/2025 07:56 PM Eastern

Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.

Xencor NASDAQ:XNCR

$8.14 -0.26 (-3.10%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$8.10 -0.04 (-0.43%)

As of 06/27/2025 06:44 PM Eastern

Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It develops Plamotamab, a bispecific antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma; Vudalimab, a bispecific antibody, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer and other solid tumor types. The company is also developing XmAb306, which is in Phase I clinical trial to treat solid tumors; XmAb104, which is in Phase II clinical trial to treat patients with selected solid tumors; XmAb564 that is in Phase Ia clinical trial to treat autoimmune diseases; AMG 509, which is in Phase I clinical trial to treat prostate cancer; XmAb819 for patients with renal cell carcinoma; XmAb541 for the treatment of ovarian cancer; and XmAb662 which is in Phase I clinical trial to treat patients with solid tumors. In addition, the company develops VIR-3434, which is in Phase II clinical trial for patients with hepatitis B virus infection; and VIR-2482 that is in Phase 2 clinical trial to trat hepatitis B virus. The company develops AIMab7195 to reduce blood serum levels of IgE that mediates allergic responses and allergic disease; Obexelimab to treat autoimmune disease; and Xpro1595 to treat patients with Alzheimer's disease, and depression. It has a license agreement with Caris Life Sciences. Xencor, Inc. was incorporated in 1997 and is headquartered in Pasadena, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time